Cannabinoid–opioid interactions during neuropathic pain and analgesia
- 28 February 2010
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 10 (1), 80-86
- https://doi.org/10.1016/j.coph.2009.09.009
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Central antinociception induced by µ‐opioid receptor agonist morphine, but not δ‐ or κ‐, is mediated by cannabinoid CB1 receptorBritish Journal of Pharmacology, 2009
- Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and InflammationThe AAPS Journal, 2009
- The μ‐opioid receptor agonist morphine, but not agonists at δ‐ or κ‐opioid receptors, induces peripheral antinociception mediated by cannabinoid receptorsBritish Journal of Pharmacology, 2008
- Advances in the field of cannabinoid–opioid cross‐talkAddiction Biology, 2008
- Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic painPain, 2006
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006
- μ Opioid receptors and analgesia at the site of a peripheral nerve injuryAnnals of Neurology, 2003
- Inhibition of opioid-degrading enzymes potentiates Δ9-tetrahydrocannabinol-induced antinociception in miceNeuropharmacology, 1998
- Δ-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the ratLife Sciences, 1997
- Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptidesCellular and Molecular Neurobiology, 1995